Gilead Sciences Inc diskutieren
Gilead Sciences Inc
WKN: 885823 / Symbol: GILD / Name: Gilead Sciences / Aktie / Biotechnologie & medizinische Forschung / Large Cap /
102,98 €
0,39 %
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at JPMorgan Chase & Co. from $100.00 to $105.00. They now have an "overweight" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at BMO Capital Markets from $94.00 to $102.00. They now have an "outperform" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Oppenheimer Holdings Inc. from $95.00 to $105.00. They now have an "outperform" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $110.00 price target on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Mizuho from $90.00 to $100.00. They now have an "outperform" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Oppenheimer Holdings Inc. from $105.00 to $115.00. They now have an "outperform" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $113.00 price target on the stock, up previously from $87.00.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at JPMorgan Chase & Co. from $105.00 to $115.00. They now have an "overweight" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Piper Sandler from $105.00 to $110.00. They now have an "overweight" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Wells Fargo & Company from $105.00 to $120.00. They now have an "overweight" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at BMO Capital Markets from $110.00 to $115.00. They now have an "outperform" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a "hold" rating to a "buy" rating. They now have a $120.00 price target on the stock, up previously from $80.00.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Oppenheimer Holdings Inc. from $115.00 to $132.00. They now have an "outperform" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Wells Fargo & Company from $120.00 to $140.00. They now have an "overweight" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Bank of America Co. from $116.00 to $126.00. They now have a "buy" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Morgan Stanley from $123.00 to $130.00. They now have an "overweight" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at JPMorgan Chase & Co. from $120.00 to $130.00. They now have an "overweight" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Morgan Stanley from $130.00 to $135.00. They now have an "overweight" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $132.00 to $125.00. They now have an "outperform" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at Needham & Company LLC from a "hold" rating to a "buy" rating. They now have a $133.00 price target on the stock.
Ratings data for GILD provided by MarketBeat
Neueste Beiträge
Guggenheim in Accenture plc A diskutieren